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Abstract 
     We developed a simple and sensitive stable-isotope dilution method for the quantification of 
3-hydroxyglutaric acid (3HGA) and glutaric acid (GA) in body fluids.  In our method, tert-
butyldimethylsilyl derivatives of 3HGA and GA were measured with a conventional electron-impact 
ionization mode in gas chromatography-mass spectrometry. The control values for 3HGA in 
nmol/ml were 0.15 ± 0.08 (serum; n = 10) and 0.07 ± 0.03 (CSF; n = 10). In addition, 
glutarylcarnitine and free carnitine were quantified by electrospray tandem mass spectrometry. Using 
these methods, we monitored 3HGA, GA, and glutarylcarnitine in the body fluids of three patients 
with glutaric aciduria type 1 found during newborn screening. None of the patients had experienced 
neurological strokes, which are possibly caused by the accumulation of 3HGA, at 15 to 24 months of 
age under a disease-specific treatment, including carnitine supplementation. Our data showed that 
3HGA levels were relatively high in some serum samples with lower glutarylcarnitine and carnitine 
levels, suggesting that carnitine supplementation may play a role in preventing the accumulation of 
3HGA in patients with this disease. 
 
1. Introduction 
     Glutaric aciduria type 1 (GA 1; McKusick 231670) is an autosomal recessive disorder caused 
by mutations in the glutaryl-CoA dehydrogenase (GCDH; EC 1.3.99.7) gene. The deficiency of 
GCDH in the metabolism of lysine, hydroxylysine, and tryptophan leads to the accumulation of 
glutaric acid (GA), 3-hydroxyglutaric acid (3HGA), glutaconic acid [1], and glutarylcarnitine [2] in 
body fluids. The clinical picture of this disease features abrupt neurological deterioration with focal 
striatal necrosis in infancy, often after infectious illnesses [3]. 3HGA is thought to be a possible cause 
of this phenomenon [4]. The main treatments for GA 1 are the restriction of amino acids as 
precursors of glutaryl-CoA, carnitine supplementation, and avoidance of fasting [3]. Such disease-
specific therapy has improved the outcome of asymptomatic GA 1 patients found in a recent 
newborn-screening program in which the high glutarylcarnitine levels in dried blood spots of the 
patients were detected by tandem mass spectrometry (MS-MS) [3,5]. Thus, it is important to monitor 
the levels of 3HGA and the related metabolites in body fluids to evaluate the efficacy of the therapy. 
     Schor et al. reported a stable isotope dilution method using ammonia chemical ionization and 
negative-ion/selected-ion monitoring as a sensitive and accurate GC-MS measurement of 3HGA [6]. 
Although this method is highly sensitive to quantify 3HGA levels in control CSF or amniotic fluid, it 
may not be practical to use ammonia as a reagent gas in routine laboratory work because it is 
difficult to handle. Thus, we developed a practical but sensitive method using a conventional 
electron-impact ionization (EI) mode for the GC-MS measurement of 3HGA and GA as tert-
butyldimethylsilyl (tBDMS) derivatives. In our method, the gas chromatographic separation between 
3HGA and 2-hydroxyglutaric acid (2HGA), which is increased in 2-hydroxyglutaric acidurias [7], 
was achieved using a capillary column with a polar liquid phase. Using this method, we measured 
the related metabolites in the body fluids of three GA 1 patients who were identified in our MS-MS 
newborn-screening program. 
 
2. Experimental 
2.1. Materials 
2.1.1. Biological samples 
     Three Japanese patients with GA 1 (MM, HK, and CH) were identified during MS-MS 
newborn screening. The glutarylcarnitine levels in dried blood spots of the patients were 2.22, 4.40, 
and 1.95 nmol/ml, respectively, with a cutoff of 0.8 nmol/ml. GCDH activities in lymphocytes [8] in 
all patients were below the detection limit of 0.10 pmol/min/106 cells, with a control range of 3.43-
6.15. CSF samples were collected from all patients twice, before therapy and 3 to 12 months later. 
Informed consent was obtained before sample collection. 
    All the patients had been treated with protein-restricted diets, carnitine supplementation, and 
prompt intravenous fluid infusions in cases of decreased caloric intake due to febrile illnesses or 
gastroenteritis. Patient MM was floppy and had delayed development. Her developmental quotient 
(DQ) was 50 during her early infancy, but it had markedly improved to 96 by the time she was 24 
months. Patients HK and CH showed normal development up to the ages of 20 months and 15 
months, respectively. 
     Frozen serum, CSF, and urine specimens were transferred to our laboratory and stored in a 
freezer until analysis. Reference body fluid samples were obtained from hospitalized children, ages 2 
months to 14 years, who did not have GA 1. 
 
2.1.2. Chemicals 
     3-Hydroxyglutaric acid and 3-hydroxy[2H4]glutaric acid were purchased from the VU Medical 
Center Metabolic Laboratory (Amsterdam, The Netherlands). [2H4]Glutaric acid and [2H3]carnitine 
were purchased from Cambridge Isotope Laboratories (Andover, MA, USA). [2H9]Glutarylcarnitine 
was synthesized in our laboratory [9].  Glutaric acid, 2-hydroxyglutaric acid, butanolic HCl (10%), 
HPLC-grade acetonitrile, methanol, and distilled water were purchased from Nacalai Tesque (Kyoto, 
Japan). N-Methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide (MTBSTFA) was purchased from 
GL Science (Tokyo, Japan). 
 
2.2. Methods 
2.2.1. Sample preparation 
     GA and 3HGA concentrations in body fluids were determined by isotope-dilution methods. A 
mixture (0.45 ml) containing 0.05 - 0.2 ml of serum or CSF, 0.2 ml of saturated NaCl solution, 0.01 
ml of 4N HCl, 0.02 ml of 2 mg/L of [2H4]3HGA, and 0.02 ml of 4mg/L of [2H4]GA was extracted 
twice with 2 ml of ethylacetate. The combined solvent layer was dried under an N2 stream, and the 
dry residue was dissolved in 0.04 ml of MTBSTFA and heated at 100ºC for 30 min. For the analysis 
of urine samples, a mixture of an aliquot of urine containing 0.005 - 0.01 mg of creatinine (Cr), 0.02 
ml of 0.05 mg/ml of [2H4]3HGA, and 0.02 ml of 0.1mg/ml of [2H4]GA was incubated with urease at 
37ºC for 15 min and deproteinized using methanol [10]. The supernatant was dried under an N2 
stream, and the dry residue was dissolved in 0.1 ml of MTBSTFA and heated at 100ºC for 30 min. 
     For recovery determination, a mixture containing 0.1 ml of control serum, spiked with 0.005, 
0.01, or 0.02 ml of 2 mg/L of 3HGA and 4 mg/L of GA, 0.2 ml of saturated NaCl solution, and 0.01 
ml of 4N HCl was extracted with ethylacetate. The extract combined with 0.02 ml of 2 mg/L of 
[2H4]3HGA and 0.02 ml of 4 mg/L of [2H4]GA was dried and derivatized. On the other hand, a 
mixture of 0.005, 0.01, or 0.02 ml of 2 mg/L of 3HGA and 4mg/L of GA, 0.02 ml of 2 mg/L of 
[2H4]3HGA, and 0.02 ml of 4 mg/L of [2H4]GA was dried directly and derivatized. For the test with 
the respective amount of spiked 3HGA and GA, three samples of each were measured by GC-MS, 
and the mean values were compared. Correction with the amounts of 3HGA and GA in the control 
serum specimen was done. 
    For acylcarnitine measurements by MS-MS [11], a mixture of 0.012 ml of the sample and 0.44 
ml of methanol solution with stable isotope-labeled acylcarnitines, including [2H9]glutarylcarnitine 
and [2H3] carnitine, was centrifuged. The supernatant was dried and derivatized with butanolic HCl, 
dried again, and then dissolved in 50% acetonitrile. 
 
2.2.2. Gas chromatography and mass spectrometry conditions 
     For serum or CSF samples, GC-MS analysis was performed on a model QP5050 gas 
chromatograph-mass spectrometer (Shimadzu, Kyoto, Japan). Chromatographic separation was 
achieved on a capillary column, SPB-50 (30 m x 0.25 mm inner diameter, film thickness 0.25 μm) 
(Supelco, Tokyo, Japan). One microliter of the processed samples was injected using the splitless 
mode at a temperature of 280ºC. The oven temperature was programmed to rise from 50ºC to 170ºC 
at a rate of 10ºC /min, to 230ºC at 5ºC /min, and to 290ºC at 10ºC /min. The mass spectrometer was 
operated under a positive EI mode, and the intensities of the ion, m/z 433 for 3HGA, m/z 437 for 
[2H4]3HGA, m/z 303 for GA, and m/z 307 for [2H4]GA, were recorded using a selected ion 
monitoring (SIM) mode. For urine samples, GC-MS analysis was performed on a model SSQ710 
single-stage mass spectrometer (ThermoElectron, Yokohama, Japan) equipped with a model 
HP5890 gas chromatograph (Yokogawa, Tokyo, Japan). The measurement conditions were the 
same as those in the measurement by QP5050. 
 
2.2.3. Tandem mass spectrometry conditions 
     Acylcarnitines were analyzed by electrospray MS-MS using a model TSQ7000 triple-stage 
mass spectrometer (ThermoElectron, Yokohama, Japan) [11]. Flow injection analysis was done. 
Precursor ion scanning using a product ion m/z 85 was performed, and the peak heights of m/z 218 
for carnitine, m/z 221 for [2H3]carnitine, m/z 388 for glutarylcarnitine, and 397 for 
[2H3]glutarylcarnitine were used for quantification. 
 
3. Results 
     The mass spectra of 3HGA and GA as tBDMS derivatives under positive EI conditions are 
shown in Fig. 1. The fragment ions [M-57]+, m/z 433 for 3HGA and m/z 303 for GA, were 
identified as prominent ions. The labeled 3HGA and GA showed the ions [M-57]+, m/z 437 and m/z 
307, respectively (data not shown). Typical SIM chromatograms of a control serum sample are 
shown in Fig. 2. Quantification was performed using peak areas of the designated ion on SIM 
chromatograms. Using QP5050 GC-MS, the linearity of the calibration curve for added 3HGA was 
observed over the concentration range 0.017-3.4 nmol/ml: slope = 0.85, intercept = 0.008, and 
r2=0.999 and, for added GA, over the concentration range 0.03 to 30 nmol/ml: slope = 0.97, intercept 
= 0.016, and r2=0.998. Using SSQ710 GC/MS, the linearity of the calibration curve for added 3HGA 
was observed over the concentration range 0.34-270 nmol/ml: slope = 0.86, intercept = 0.77, and 
r2=0.999 and, for added GA, over the concentration range 1.5 to 760 nmol/ml: slope = 0.95, intercept 
= 1.6, and r2=0.998. 
     The limits of quantification (signal-to-noise ratio of 10:1) for 3HGA and GA in aqueous 
solution were 0.017 nmol/ml and 0.0019 nmol/ml, respectively, using QP5050 GC-MS, and 0.34 
nmol/ml and 0.057 nmol/ml, respectively, using SSQ710 GC-MS. 
     The recovery for 3HGA was 47, 48, or 51% at the concentration of 0.68, 1.35, or 2.7 nmol/ml, 
and that for GA was 85, 86, or 83% at 1.52, 3.0, or 6.1 nmol/ml, respectively. 
     The intra-assay variabilities were tested by the analysis of six samples processed at the same 
time using a control serum specimen with or without spiked 3HGA and GA or a patient’s urine 
specimen, and the inter-assay variabilities were tested by processing and analyzing one sample on 6 
different days. The coefficients of variation are listed in Table 1. 
    The control (n = 10) values for 3HGA in serum (nmol/ml), CSF (nmol/ml), and urine 
(mmol/mol Cr) were 0.15 ± 0.08, 0.07 ± 0.03, and 1.3 ± 0.7, respectively, and those for GA were 
0.68 ± 0.36, 0.93 ± 0.38, and 3.8 ± 2.0, respectively. Those for glutarylcarnitine in serum (nmol/ml) 
and CSF (nmol/ml) were < 0.3 and < 0.1, respectively. 
   The concentrations of 3HGA and GA in urine, serum, and CSF samples of the three patients with 
GA 1 are shown in Fig. 3. The amounts of urinary GA of all three patients were large during the 
newborn period. Those of patient HK remained high, while those of the other patients decreased 
markedly during treatment. Regardless of the urinary GA levels of the patients, moderate amounts of 
urinary 3HGA were observed during infancy. A similar time course was observed in the patients’ 
serum levels of 3HGA and GA. The serum levels of 3HGA in patient MM were similar to those in 
patient HK, although the serum levels of GA in patient HK were markedly higher than those in 
patient MM. The CSF levels of 3HGA in the patients were kept low during the newborn period and 
later infancy, although those of GA were markedly high. 
     The relationship between the patients’ 3HGA and GA levels in serum or CSF is shown in Fig. 
4. Although the concentrations of 3HGA were roughly related to those of GA in most serum samples, 
those of 3HGA in some serum samples of patient MM were relatively high compared with those of 
GA. Furthermore, the 3HGA concentrations in the CSF of all patients were distributed at similar low 
levels regardless of GA levels. 
     The relationship between 3HGA and glutarylcarnitine or free carnitine concentrations in the 
serum or CSF of the patients is shown in Fig. 4. In most samples, the 3HGA concentrations were 
lower than the glutarylcarnitine concentrations. The 3HGA concentrations in some serum samples of 
patient MM, however, were higher than the glutarylcarnitine concentrations. Although 3HGA and 
free carnitine levels were not correlated, those of 3HGA were high when those of free carnitine were 
low in some serum samples of patients MM and CH. 
 
4. Discussion 
     In GA 1 patients, glutaryl-CoA is accumulated due to the deficiency of glutaryl-CoA 
dehydrogenase. The accumulation of glutaryl-CoA leads elevated levels of 3HGA, GA, and 
glutarylcarnitine in body fluids [1,2]. Although the exact mechanism of the formation of 3HGA is 
not known, 3HGA accumulation in the central nervous system is thought to be a possible cause of 
neurological deterioration with focal striatal necrosis in infancy [4]. Glutarylcarnitine is formed 
through the combination of glutaryl-CoA and carnitine, and the urinary excretion of glutarylcarnitine 
leads to carnitine deficiency [2]. Although the supplementation of carnitine is thought to be an 
effective therapy for GA 1 patients [3], the mechanism has not been clarified. Thus, 3HGA and the 
related metabolites should be monitored as indicators of metabolic derangement in GA 1 patients. 
     We have developed a new stable isotope dilution method for the measurement of 3HGA and 
GA in body fluids as tBDMS derivatives. This method is sensitive enough for use in routine 
laboratory work, especially for the analysis in GA 1 patients. The limit of quantification of 0.017 
nmol/ml of 3HGA in serum or CSF of this method, using 0.2 ml of specimen, is comparable with 
that of 0.01 nmol/ml in the reported method, the chemical ionization mode using ammonia as a 
reagent gas and 1.0 ml of processed specimen [6]. Under a positive EI mode, 3HGA and GA as 
tBDMS derivatives produce positive fragment ions of [M-57]+ with higher intensities in higher mass 
numbers than those produced by trimethylsily derivatives. We used an initial GC oven temperature 
as low as 50ºC to increase the sample introduction into the capillary column by splitless injection. In 
addition, in our method, baseline separation between 3HGA and 2-hydroxyglutaric acid as tBDMS 
derivatives was achieved using a capillary column with a polar liquid phase, as reported previously 
[6], for reliable and accurate quantification. 
     Our method is simple, since both the hydroxy and carboxy groups of 3HGA are derivatized 
using a single reagent. It is unnecessary to use ammonia as a reagent gas, which is difficult to 
regulate in the laboratory. Although we adopted a convenient solvent extraction method in which the 
recovery of 3HGA was about 50%, some increment in sensitivity can be obtained if solid-phase 
extraction is used [1]. Indeed, we derivatized urease-treated urine specimens without the extraction 
process and were able to perform the sensitive analysis using an aliquot of control urine containing 
levels as low as 0.01 mg Cr. 
     Patient HK showed large amounts of GA in urine and was thought to be a high excretor of GA 
[1], while the amounts of GA in the other patients decreased later in infancy. In GA 1 patients, 
3HGA in urine is thought to be disease-specific and the only diagnostic metabolite [3]. The amounts 
of 3HGA in the urine of our patients, even later in infancy, were considerably higher than those of 
controls. The changes in the levels of 3HGA and GA in the patients’ serum were similar to those in 
urine. However, striatal injury, which is characteristic of GA 1, can be associated with any excretion 
patterns of organic acids [3]. Thus, the measurement of the related metabolites in CSF or brain 
tissues seems important for evaluating the pathological effects on the central nervous system. 
     Recently, region-specific analysis of organic acids and acylcarnitines in the post-mortem brain 
of a GA 1 patient who reportedly had not been treated with carnitine revealed higher concentrations 
of 3HGA than those of GA or glutarylcarnitine in the putamen [4]. Indeed, the glutarylcarnitine 
levels in CSF of this patient were rather lower than those shown in our study, while the 3HGA levels 
were much higher than those in our patients. This finding may be due partly to a secondary carnitine 
deficiency of the patient and partly to the use of stable isotope-labeled octanoylcarnitine as an 
internal standard to quantify glutarylcarnitine. Since the intensity of product ion m/z 85 produced 
from glutarylcarnitine in the collision-induced dissociation process of MS/MS measurement is 
considerably lower than that from octanoylcarnitine, the glutarylcarnitine values in the report 
mentioned above are thought to be lower than those in our study using labeled glutarylcarnitine as an 
internal standard. 
     Carnitine is reportedly transported across the blood-brain barrier by a low-affinity carrier 
system [12,13], and it is synthesized and used locally in the brain [14]. We observed increased levels 
of carnitine in the CSF of a patient with propionic acidemia after carnitine supplementation [15]. In 
the present study, carnitine levels in CSF of the patients with GA 1 were not markedly increased by 
carnitine supplementation. Nevertheless, it is possible that carnitine supplementation at least 
prevented a secondary carnitine deficiency in these patients. In addition, it is worth mentioning that 
the 3HGA levels were relatively high in some serum samples that contained low levels of carnitine 
because they were collected when the patients did not take carnitine due to infectious diseases or 
other problems. Thus, our data suggest that carnitine supplementation may play an important role in 
preventing the accumulation of 3HGA not only in serum but also in CSF, that is, in the central 
nervous system. 
     Fortunately, our GA 1 patients identified during MS/MS newborn screening have not shown 
any neurological strokes. The present study did not show whether 3HGA levels in CSF are related to 
central nervous system abnormalities. Further careful monitoring of the levels of the related 
metabolites in CSF as well as in the other body fluids is needed. 
     In conclusion, our method for 3HGA and GA promotes an adequate evaluation of GA 1 
patients identified in newborn screening. 
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Legends 
Fig. 1  Electron-impact ionization mass spectra of tert-butyldimethylsilyl derivatives of 3HGA (A) 
and GA (B). 
 
Fig. 2  Selected ion chromatograms of 3HGA and GA in a control serum sample. 2HGA, 2-
hydroxyglutaric acid. 
 
Fig. 3  3HGA and GA levels in urine (A), plasma (B), and CSF (C) of three patients with GA 1. 
Open circle for 3HGA and closed circle for GA in patient MM, open diamond for 3HGA and closed 
diamond for GA in HK, and open triangle for 3HGA and closed triangle for GA in CH. 
 
Fig. 4  The relationship between 3HGA and GA levels in serum and CSF. Closed circle for serum 
and open circle for CSF of patient MM, closed diamond for serum and open diamond for CSF of 
HK, and closed triangle for serum and open triangle for CSF of CH. 
 
Fig. 5 The relationship between 3HGA and glutarylcarnitine levels (A) and between 3HGA and free 
carnitine levels (B) in serum and CSF. Closed circle for serum and open circle for CSF of patient 
MM, closed diamond for serum and open diamond for CSF of HK, and closed triangle for serum 
and open triangle for CSF of CH. 
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